AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37473848 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care as usual
Number of subjects: 2320
Study 37473848 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE program
Number of subjects: 2320
Study 37473964 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg mRNA-1273 vaccine via npMNA patch (ID-patch group)
Number of subjects: 20
Study 37473964 — intervention group
Group type: COMPARATOR
Intervention: 20 µg mRNA-1273 vaccine via intramuscular injection (IM-control group)
Number of subjects: 20
Study 37474106 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional optical (3DO) imaging
Number of subjects: 634
Study 37474106 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 634
Study 37474136 — intervention group
Group type: EXPERIMENTAL
Intervention: Bailout angioplasty
Number of subjects: 348
Study 37474136 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 348
Study 37474169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low-energy diet (ILED)
Number of subjects: 12
Study 37474169 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-energy diet (CLED)
Number of subjects: 12
Study 37474181 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine (AQ) supplementation at doses of 4, 24, and 44 g administered daily for 10 days.
Number of subjects: 0
Study 37474181 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (placebo control).
Number of subjects: 0
Study 37474181 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine (AQ) supplementation.
Number of subjects: 0
Study 37474180 — intervention group
Group type: COMPARATOR
Intervention: TRAIL (Telerehabilitation with Aims to Improve Lower extremity recovery poststroke) - 4-week progressive exercise and self-management intervention delivered via video-conferencing, 8 sessions with a physical therapist.
Number of subjects: 96
Study 37474180 — intervention group
Group type: COMPARATOR
Intervention: TRAIL
Number of subjects: 96
Study 37474180 — intervention group
Group type: COMPARATOR
Intervention: EDUCATION (attention-controlled education programme)
Number of subjects: 96
Study 37474184 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative maximum C-reactive protein concentration
Number of subjects: 1400
Study 37474184 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of three inflammatory biomarkers (interleukin 6, procalcitonin, and copeptin)
Number of subjects: 1400
Study 37474234 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 1566
Study 37474234 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine
Number of subjects: 1566
Study 37474234 — intervention group
Group type: COMPARATOR
Intervention: standard of care (control)
Number of subjects: 1566
Study 37474242 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based anaesthesia
Number of subjects: 1195
Study 37474242 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-based anaesthesia
Number of subjects: 1195
Study 37474241 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based anaesthesia
Number of subjects: 1195
Study 37474241 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-based anaesthesia
Number of subjects: 1195
Study 37474354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal medical device (1 ovule per day for 15 days)
Number of subjects: 47
Study 37474354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal medical device
Number of subjects: 47
Study 37474355 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Optical Coherence Tomography software (OctPlus)
Number of subjects: 74
Study 37474632 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (front-line treatment)
Number of subjects: 136
Study 37474689 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug sensitivity tests on circulating tumor cell-derived organoids (cancer avatars)
Number of subjects: 12
Study 37474720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib 40 mg orally twice daily plus tislelizumab 200 mg intravenously every 3 weeks
Number of subjects: 180
Study 37474720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib plus tislelizumab in triple-negative breast cancer (TNBC) arm
Number of subjects: 180
Study 37474720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib plus tislelizumab
Number of subjects: 180
Study 37474729 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine treatment
Number of subjects: 365
Study 37474729 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blocker use
Number of subjects: 365
Study 37474729 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 365
Study 37474729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower CRP levels
Number of subjects: 365
Study 37474729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower C3 levels
Number of subjects: 365
Study 37474729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower hemoglobin levels
Number of subjects: 365
Study 37474729 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe kidney dysfunction
Number of subjects: 365
Study 37474761 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.08 g% breath alcohol concentration)
Number of subjects: 47
Study 37474761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 37474784 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative thalamic volume
Number of subjects: 301
Study 37474784 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up cognitive test after 3 months
Number of subjects: 301
Study 37474823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudexacianinium 0.3 mg
Number of subjects: 12
Study 37474823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudexacianinium 1.0 mg
Number of subjects: 12
Study 37474823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudexacianinium 3.0 mg
Number of subjects: 12
Study 37474829 — intervention group
Group type: COMPARATOR
Intervention: eHealth platform (online group)
Number of subjects: 205
Study 37474829 — intervention group
Group type: COMPARATOR
Intervention: eHealth platform with self-monitoring devices (device group)
Number of subjects: 205
Study 37474829 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 205
Study 37474950 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 509
Study 37474950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglia (DRG) stimulation
Number of subjects: 509
Study 37474950 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PROs
Number of subjects: 509
Study 37474971 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (probiotic mixture including Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium, total 2.5 × 10)
Number of subjects: 0
Study 37474971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37474974 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN
Number of subjects: 240
Study 37474974 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 240
Study 37475004 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib plus endocrine therapy (ET)
Number of subjects: 89
Study 37475004 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib plus ET
Number of subjects: 89
Study 37475009 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin treatment
Number of subjects: 367
Study 37475009 — intervention group
Group type: COMPARATOR
Intervention: Standard post-MI treatment (placebo)
Number of subjects: 367
Study 37475033 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet
Number of subjects: 180
Study 37475033 — intervention group
Group type: COMPARATOR
Intervention: Moderate-carbohydrate plate-method diet
Number of subjects: 180
Study 37475036 — intervention group
Group type: EXPERIMENTAL
Intervention: Written physical activity prescription with pedometer and logbook
Number of subjects: 121
Study 37475036 — intervention group
Group type: COMPARATOR
Intervention: Verbal advice to do at least 15 minutes of rapid walking or equivalent daily
Number of subjects: 121
Study 37475116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cecolin 9
Number of subjects: 553
Study 37475116 — intervention group
Group type: COMPARATOR
Intervention: Gardasil 9
Number of subjects: 553
Study 37475685 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention in the MUO group
Number of subjects: 0
Study 37475685 — intervention group
Group type: COMPARATOR
Intervention: Metabolically healthy lean group
Number of subjects: 0
Study 37475685 — intervention group
Group type: COMPARATOR
Intervention: Metabolically healthy obesity group
Number of subjects: 0
Study 37475685 — intervention group
Group type: COMPARATOR
Intervention: Metabolically unhealthy obesity (MUO) group
Number of subjects: 0
Study 37475689 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet (40% protein) with ≥4 weekly servings of lean beef
Number of subjects: 106
Study 37475689 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein (NP) diet (21% protein) excluding red meat
Number of subjects: 106
Study 37475689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HP and NP diets
Number of subjects: 106
Study 37475743 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM)
Number of subjects: 0
Study 37475743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study 37475743 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 37475976 — intervention group
Group type: EXPERIMENTAL
Intervention: tSAH group
Number of subjects: 33
Study 37475976 — intervention group
Group type: COMPARATOR
Intervention: non-tSAH group
Number of subjects: 33
Study 37476005 — intervention group
Group type: EXPERIMENTAL
Intervention: InMotion intervention (24 biweekly sessions of 60 min each)
Number of subjects: 60
Study 37476005 — intervention group
Group type: EXPERIMENTAL
Intervention: InMotion intervention
Number of subjects: 60
Study 37476005 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 37476021 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Function Measure 20/32 (MFM-20/32)
Number of subjects: 27
Study 37476021 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry
Number of subjects: 27
Study 37476021 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires
Number of subjects: 27
Study 37476021 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle ultrasound
Number of subjects: 27
Study 37476021 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory function tests
Number of subjects: 27
Study 37476021 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiography
Number of subjects: 27
Study 37476021 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 27
Study 37476021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry
Number of subjects: 27
Study 37476150 — intervention group
Group type: EXPERIMENTAL
Intervention: Wear a patch monitor and a smartwatch linked to a smartphone running the Pulsewatch application
Number of subjects: 0
Study 37476150 — intervention group
Group type: COMPARATOR
Intervention: Only the cardiac patch monitor
Number of subjects: 0
Study 37476372 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab after chemoradiotherapy
Number of subjects: 101
Study 37476372 — intervention group
Group type: COMPARATOR
Intervention: Not starting durvalumab
Number of subjects: 101
Study 37476372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment diabetes and reduced hemoglobin/diffusion capacity
Number of subjects: 101
Study 37476372 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment plan disruption
Number of subjects: 101
Study 37476372 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammation and performance status
Number of subjects: 101
Study 37476572 — intervention group
Group type: EXPERIMENTAL
Intervention: LI-guided ablation
Number of subjects: 212
Study 37476572 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CF
Number of subjects: 212
Study 37476572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of good CF and adequate LI drop
Number of subjects: 212
Study 37477105 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² combined with cisplatin 75 mg/m² (HIPEC at 43°C for 90 minutes)
Number of subjects: 30
Study 37477105 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 70 mg/m²
Number of subjects: 30
Study 37477105 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m²
Number of subjects: 30
Study 37477105 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel ≤65 mg/m²
Number of subjects: 30
Study 37477106 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 0
Study 37477173 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy for 52 weeks
Number of subjects: 476
Study 37477173 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix alone for 12 weeks followed by relugolix combination therapy for 40 weeks
Number of subjects: 476
Study 37477173 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks followed by relugolix combination therapy for 28 weeks
Number of subjects: 476
Study 37477353 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated dual-marker rule-out strategy using prehospital copeptin and high-sensitivity troponin T
Number of subjects: 4351
Study 37477353 — intervention group
Group type: COMPARATOR
Intervention: Standard rule-out strategy using a 0 h/3 h rule-out strategy
Number of subjects: 4351
Study 37477771 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 1111
Study 37477771 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 1111
Study 37477771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1111
Study 37477788 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone (5 mg) added to IIN/IHN block
Number of subjects: 0
Study 37477788 — intervention group
Group type: COMPARATOR
Intervention: Control Group (normal saline) added to IIN/IHN block
Number of subjects: 0
Study 37477804 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure for 21 min per day for 12 sessions
Number of subjects: 81
Study 37477804 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure for 21 min per day for 12 sessions
Number of subjects: 81
Study 37477877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberbullying victimization
Number of subjects: 9483
Study 37477877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberbullying perpetration
Number of subjects: 9483
Study 37477877 — intervention group
Group type: EXPERIMENTAL
Intervention: Bully-victims
Number of subjects: 9483
Study 37477877 — intervention group
Group type: EXPERIMENTAL
Intervention: School dysfunction and hyperactivity/impulsivity
Number of subjects: 9483
Study 37477875 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd155-RSV low dose (1.5 × 10^10 viral particles)
Number of subjects: 201
Study 37477875 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd155-RSV high dose (5 × 10^10 viral particles)
Number of subjects: 201
Study 37477875 — intervention group
Group type: COMPARATOR
Intervention: Active comparator vaccines/placebo
Number of subjects: 201
Study 37477875 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd155-RSV (both doses)
Number of subjects: 201
Study 37477887 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal nutrition by gastrojejunal tube (GJT)
Number of subjects: 46
Study 37477967 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care access, comprehensiveness, and appropriateness during the COVID-19 pandemic.
Number of subjects: 875934
Study 37477967 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicators specific to evidence-based recommendations for care in patients with diabetes and heart failure.
Number of subjects: 875934
Study 37477967 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient sociodemographic characteristics and multimorbidity.
Number of subjects: 875934
Study 37478110 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 950
Study 37478110 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and on-site influenza vaccination
Number of subjects: 950
Study 37478110 — intervention group
Group type: EXPERIMENTAL
Intervention: Free access to vaccination
Number of subjects: 950
Study 37478110 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory influenza vaccination
Number of subjects: 950
Study 37478213 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 5 L/minute
Number of subjects: 54
Study 37478213 — intervention group
Group type: COMPARATOR
Intervention: Fresh gas flow of 10 L/minute
Number of subjects: 54
Study 37478283 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined local therapy and CAR-GPC3 T-cell therapy
Number of subjects: 0
Study 37478389 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance tumor regression grade (MR-TRG)
Number of subjects: 121
Study 37478389 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 121
Study 37478390 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 201
Study 37478390 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 201
Study 37478401 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy using a self-inactivating lentiviral vector expressing human WAS complementary DNA after busulfan and fludarabine conditioning
Number of subjects: 5
Study 37478401 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy
Number of subjects: 5
Study 37478529 — intervention group
Group type: EXPERIMENTAL
Intervention: TranS-C plus usual care
Number of subjects: 108
Study 37478529 — intervention group
Group type: COMPARATOR
Intervention: Usual care followed by delayed treatment with TranS-C
Number of subjects: 108
Study 37478883 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy with immunotherapy (I-SABR)
Number of subjects: 156
Study 37478883 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 156
Study 37478886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing intervention (audiological counselling and provision of hearing aids)
Number of subjects: 977
Study 37478886 — intervention group
Group type: COMPARATOR
Intervention: Health education control (individual sessions with a health educator covering topics on chronic disease prevention)
Number of subjects: 977
Study 37478969 — intervention group
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 0.5%
Number of subjects: 245
Study 37478969 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 245
Study 37478977 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT)
Number of subjects: 3095
Study 37479050 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused psychodynamic interview
Number of subjects: 91
Study 37479050 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 91
Study 37479139 — intervention group
Group type: EXPERIMENTAL
Intervention: givosiran 2.5 mg/kg
Number of subjects: 94
Study 37479139 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 94
Study 37479372 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat (15 mg/day)
Number of subjects: 221
Study 37479372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 37479372 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat
Number of subjects: 221
Study 37479373 — intervention group
Group type: EXPERIMENTAL
Intervention: AXER-204 (200 mg)
Number of subjects: 51
Study 37479373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 37479483 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 33
Study 37479483 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus intermittent dabrafenib and trametinib
Number of subjects: 33
Study 37479483 — intervention group
Group type: COMPARATOR
Intervention: Cohort 1 (Pembrolizumab)
Number of subjects: 33
Study 37479483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2 (Pembrolizumab + intermittent dabrafenib and trametinib)
Number of subjects: 33
Study 37479483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 3 (Pembrolizumab + intermittent dabrafenib and trametinib)
Number of subjects: 33
Study 37479483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 4 (Pembrolizumab + intermittent dabrafenib and trametinib)
Number of subjects: 33
Study 37479483 — intervention group
Group type: COMPARATOR
Intervention: Cohort 1
Number of subjects: 33
Study 37479483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2
Number of subjects: 33
Study 37479483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 3
Number of subjects: 33
Study 37479483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 4
Number of subjects: 33
Study 37479506 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-visit ANC combined with telemedicine services
Number of subjects: 1476
Study 37479506 — intervention group
Group type: COMPARATOR
Intervention: Routine ANC
Number of subjects: 1476
Study 37479514 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindmore Postoperative version (Mindmore-P) preoperatively and on postoperative day (POD) 1 or 2 as well as 2-3 weeks after surgery
Number of subjects: 50
Study 37479514 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindmore-P
Number of subjects: 50
Study 37479514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nu-DESC (Nursing Delirium Screening Scale)
Number of subjects: 50
Study 37479514 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale, Geriatric Depression Scale-15, 12-item WHO Disability Assessment Schedule 2.0, Swedish web version Quality of Recovery Scale (SwQoR)
Number of subjects: 50
Study 37479514 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews approximately 1 month after surgery
Number of subjects: 50